07:00 , Jun 2, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Cystathionine β synthase (CBS)

Endocrine/metabolic disease INDICATION: Metabolic Mouse studies suggest CBS could help treat homocystinuria, in which deficiency of the enzyme can cause accumulation of homocysteine in serum and organs. In a mouse model of homocystinuria with non-lethal CBS deficiency,...
08:00 , Mar 3, 2014 |  BioCentury  |  Emerging Company Profile

CBS: Sniffing out cancer therapy

CBS Therapeutics Inc. is developing first-in-class inhibitors of cystathionine beta synthase that could synergize with existing therapies to treat both KRAS-mutant and wild-type metastatic colorectal cancer. Cystathionine beta synthase (CBS) is found in many cell types...
07:00 , Aug 15, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Colorectal cancer Cystathionine b-synthase (CBS) In vitro and mouse studies suggest inhibiting CBS could help treat colorectal...
07:00 , Oct 4, 2012 |  BC Innovations  |  Strategy

Buddy system for orphan disease

The Wellcome Trust has launched a program to fund early stage translational research in rare and orphan diseases. Participation in the program, dubbed the Pathfinder Award Scheme, requires academics or not-for-profits to pair up with...
08:00 , Jan 12, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Inflammatory bowel disease (IBD) Cystathionine b-synthase (CBS); cystathionase (CTH) Cell culture studies suggest blocking hydrogen sulfide...
07:00 , Sep 19, 2011 |  BC Week In Review  |  Company News

NovAliX, Fondation Jerome Lejeune deal

NovAliX and the foundation partnered to develop small molecules against cystathionine beta-synthase ( CBS) to treat Trisomy 21. NovAliX will be responsible for development under the two-year deal, which may be renewed. The genetic diseases...
07:00 , Mar 12, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Genitourinary disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Genitourinary disease ...
08:00 , Nov 6, 2008 |  BC Innovations  |  Targets & Mechanisms

Gassing hypertension

U.S. and Canadian researchers have shown that an endogenous gas, hydrogen sulfide (H2S), can function as an endothelial cell-derived relaxing factor that regulates blood pressure.1 The finding reveals potential new intervention points in hypertension, although...
07:00 , Apr 5, 1999 |  BioCentury  |  Finance

The barber's chairman

Ebb & Flow The barber's chairman Meanwhile,Anthra cited market conditions for withdrawing its NASDAQ IPO. The company is starting to generate royalty revenue, as partner Medeva launched Anthra's Valstar valrubicin in the U.S. in February...
08:00 , Jan 26, 1998 |  BioCentury  |  Finance

Vivus bowls over NBC

Ebb & Flow NBC's refusal to air Vivus' commercial for its MUSE erectile dysfunction product during the Super Bowl may be a blessing in disguise. The company is ramping up a print and TV advertising...